PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-30.95%
Negative net income growth while TRVN stands at 36.30%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
-12.50%
Negative yoy D&A while TRVN is 1.14%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
No Data
No Data available this quarter, please select a different quarter.
-0.29%
Both cut yoy SBC, with TRVN at -13.66%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
710.07%
Slight usage while TRVN is negative at -86.81%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
478.18%
A yoy AP increase while TRVN is negative at -440.43%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
8.45%
Lower 'other working capital' growth vs. TRVN's 218.85%. David Dodd would see fewer unexpected short-term demands on cash.
-100.00%
Negative yoy while TRVN is 387.79%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-8.11%
Negative yoy CFO while TRVN is 23.75%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
100.00%
CapEx growth of 100.00% while TRVN is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We expand invests by 100.00% while TRVN is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
-50.00%
We cut debt repayment yoy while TRVN is 33.33%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-32.24%
Negative yoy issuance while TRVN is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.